AbbVie (ABBV) to Acquire Stemcentrx in ~$5.8B Cash and Stock Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
AbbVie (ABBV) Tops Q1 EPS by 1c; Updates FY16 EPS Outlook
April 28, 2016 7:23 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $1.15, $0.01 better than the analyst estimate of $1.14. Revenue for the quarter came in at $5.96 billion versus the consensus estimate of $6.03 billion.
GUIDANCE:
AbbVie sees FY2016 EPS of $4.62-$4.82, versus the consensus of $4.97.
The company's 2016 adjusted... More
